Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (NCT07615283) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
China40 participantsStarted 2026-05-29
Plain-language summary
To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the combination regimen, and to assess preliminary efficacy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years old,regardless of gender;
. Centrally confirmed histopathological/cytologic diagnosis of PTCL with the following subtypes:
. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);
. Systemic anaplastic large cell lymphoma (ALK+ and ALK-);
. Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS;
. NKTCL
. and any other PTCL subtypes deemed by the investigator to be eligible for inclusion.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is still listed as 'not yet recruiting' — do you know when it's expected to open, and is it realistic to wait for it given how quickly my lymphoma may need to be treated?
2Since this is a Phase 1/2 trial and the first part is specifically figuring out safe doses and how much of these two drugs to give together, what does that mean for my personal risk compared to standard treatment options for relapsed or refractory PTCL or NK/T-cell lymphoma?
3Adebrelimab is a PD-L1 checkpoint inhibitor and SHR2554 appears to target EZH2 — can you explain how combining an immunotherapy with an EZH2 inhibitor is supposed to work against my type of lymphoma, and whether there's any early evidence this combination is promising?
4Given that one of the main things Phase 1 is measuring is dose-limiting toxicities, what kinds of serious side effects should I realistically prepare for if I were to enroll, and how would they be monitored and managed?
5Before considering this trial, are there any standard salvage therapies or other approved treatments I should try first, or is there a reason this experimental combination might actually be worth discussing as an earlier option for my specific situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Phase Ib: Dose limited toxicities (DLTs)
Timeframe: Cycle 1 (21 days)
2
Phase Ib: Recommended Phase II Dose (RP2D)
Timeframe: through Phase Ib study completion, an average of 4 months
. Met the criteria of relapsed/refractory lymphoma: Relapsed lymphoma was defined as relapsed lymphoma after achieving complete response (CR) or partial response(PR)after initial therapy. Refractory is defined as having an evaluation of progressive disease (PD) after 2 cycles, or stable disease (SD) after 4 cycles of a previous systemic therapy regimen.
Exclusion criteria
. Pregnant or lactating women;
. Patients with hemophagocytic lymphohistiocytosis;
. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.
. History of allogeneic organ transplantation;
. Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 3 years prior to the first dose of study drug (patients who received allo-HSCT \> 3 years prior to the first dose of study drug and currently have no active graft-versus-host disease \[GVHD\] are eligible to enroll);
. Known allergy or hypersensitivity to the study drugs or their related metabolites;
. Uncontrolled active infection;
. Currently participating in another clinical study, or less than 4 weeks elapsed from the end of treatment in a previous clinical study to the planned start of study treatment;